DOW JONES–The Swiss stock market ended trading on Tuesday with a positive trend. The US military intervention in Venezuela once again played no role in the market, traders said. Rather, investors were hoping for interest rate cuts from the US Federal Reserve. Investors primarily bought pharmaceutical stocks, which had been avoided at the beginning of the week. In contrast, some of the economic cyclicals that were in demand the day before were now taking profits.
The SMI gained 0.6 percent to 13,322 points. Of the 20 SMI values, there were twelve price winners and eight losers. 19.88 (previous day: 27.71) million shares were traded.
The SMI was led by pharmaceutical heavyweight Novartis, whose share price rose by 2.8 percent without any news. Alcon shares also recorded a significant increase of 2.6 percent. The ophthalmology specialist will not take over the US company Staar Surgical after its shareholders refused to approve the transaction. Also in the sector, Roche rose by 1.4 percent and Lonza by 0.4 percent.
Nestle shares were sold again (-0.4%), which market participants explained as the group recalling baby food. The affected products could be contaminated with toxins.
At Swiss Re (-0.9%), skepticism regarding the upcoming round of renewals is likely to have weighed on again. UBS shares (-1.6%) were sold in line with the European banking sector.
Contact: [email protected]
DJG/cln/ros
(END) Dow Jones Newswires
January 06, 2026 11:40 ET (16:40 GMT)
Selected leverage products on Alcon
With knock-outs, speculative investors can participate disproportionately in price movements. Simply select the lever you want and we will show you suitable open-end products on Alcon
The leverage must be between 2 and 20
Advertising